1063 related articles for article (PubMed ID: 21704236)
1. Longitudinal assessment of estimated glomerular filtration rate in apparently healthy adults: a post hoc analysis from the JUPITER study (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).
Vidt DG; Ridker PM; Monyak JT; Schreiber MJ; Cressman MD
Clin Ther; 2011 Jun; 33(6):717-25. PubMed ID: 21704236
[TBL] [Abstract][Full Text] [Related]
2. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).
Ridker PM; MacFadyen JG; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
Circ Cardiovasc Qual Outcomes; 2009 Nov; 2(6):616-23. PubMed ID: 20031900
[TBL] [Abstract][Full Text] [Related]
3. Rosuvastatin-induced arrest in progression of renal disease.
Vidt DG; Cressman MD; Harris S; Pears JS; Hutchinson HG
Cardiology; 2004; 102(1):52-60. PubMed ID: 15073451
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial.
Ridker PM; MacFadyen J; Cressman M; Glynn RJ
J Am Coll Cardiol; 2010 Mar; 55(12):1266-1273. PubMed ID: 20206456
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the prevalence and mortality risk of CKD in Australia using the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) Study GFR estimating equations: the AusDiab (Australian Diabetes, Obesity and Lifestyle) Study.
White SL; Polkinghorne KR; Atkins RC; Chadban SJ
Am J Kidney Dis; 2010 Apr; 55(4):660-70. PubMed ID: 20138414
[TBL] [Abstract][Full Text] [Related]
6. Rosuvastatin: a review of its use in the prevention of cardiovascular disease in apparently healthy women or men with normal LDL-C levels and elevated hsCRP levels.
Carter NJ
Am J Cardiovasc Drugs; 2010; 10(6):383-400. PubMed ID: 21090831
[TBL] [Abstract][Full Text] [Related]
7. Clinical risk implications of the CKD Epidemiology Collaboration (CKD-EPI) equation compared with the Modification of Diet in Renal Disease (MDRD) Study equation for estimated GFR.
Matsushita K; Tonelli M; Lloyd A; Levey AS; Coresh J; Hemmelgarn BR;
Am J Kidney Dis; 2012 Aug; 60(2):241-9. PubMed ID: 22560843
[TBL] [Abstract][Full Text] [Related]
8. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Strandberg TE; Feely J; Sigurdsson EL;
Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
[TBL] [Abstract][Full Text] [Related]
9. Effect of short-term rosuvastatin treatment on estimated glomerular filtration rate.
Vidt DG; Harris S; McTaggart F; Ditmarsch M; Sager PT; Sorof JM
Am J Cardiol; 2006 Jun; 97(11):1602-6. PubMed ID: 16728222
[TBL] [Abstract][Full Text] [Related]
10. Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER).
Everett BM; Glynn RJ; MacFadyen JG; Ridker PM
Circulation; 2010 Jan; 121(1):143-50. PubMed ID: 20026779
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal analysis of performance of estimated glomerular filtration rate as renal function declines in chronic kidney disease.
Lee D; Levin A; Roger SD; McMahon LP
Nephrol Dial Transplant; 2009 Jan; 24(1):109-16. PubMed ID: 18755849
[TBL] [Abstract][Full Text] [Related]
12. A novel model of cardiovascular risk based on kidney function.
Foley RN; Collins AJ
Am J Nephrol; 2011; 34(6):505-11. PubMed ID: 22056923
[TBL] [Abstract][Full Text] [Related]
13. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein.
Ridker PM; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Khurmi NS; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
Am J Cardiol; 2007 Dec; 100(11):1659-64. PubMed ID: 18036365
[TBL] [Abstract][Full Text] [Related]
14. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
Mora S; Ridker PM
Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
[TBL] [Abstract][Full Text] [Related]
15. Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER).
Ridker PM; MacFadyen J; Libby P; Glynn RJ
Am J Cardiol; 2010 Jul; 106(2):204-9. PubMed ID: 20599004
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the MDRD Study and the CKD-EPI Study equations in evaluating trends of estimated kidney function at population level: findings from the National FINRISK Study.
Juutilainen A; Kastarinen H; Antikainen R; Peltonen M; Salomaa V; Tuomilehto J; Jousilahti P; Sundvall J; Laatikainen T; Kastarinen M
Nephrol Dial Transplant; 2012 Aug; 27(8):3210-7. PubMed ID: 22492828
[TBL] [Abstract][Full Text] [Related]
17. Validation of the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation in advanced chronic renal failure.
Teruel Briones JL; Gomis Couto A; Sabater J; Fernández Lucas M; Rodríguez Mendiola N; Villafruela JJ; Quereda C
Nefrologia; 2011; 31(6):677-82. PubMed ID: 22130283
[TBL] [Abstract][Full Text] [Related]
18. Are prediction equations for glomerular filtration rate useful for the long-term monitoring of type 2 diabetic patients?
Fontseré N; Salinas I; Bonal J; Bayés B; Riba J; Torres F; Rios J; Sanmartí A; Romero R
Nephrol Dial Transplant; 2006 Aug; 21(8):2152-8. PubMed ID: 16702203
[TBL] [Abstract][Full Text] [Related]
19. Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study.
Athyros VG; Karagiannis A; Ganotakis ES; Paletas K; Nicolaou V; Bacharoudis G; Tziomalos K; Alexandrides T; Liberopoulos EN; Mikhailidis DP;
Curr Med Res Opin; 2011 Aug; 27(8):1659-68. PubMed ID: 21714711
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) study.
Michos ED; Blumenthal RS
J Am Coll Cardiol; 2009 Mar; 53(11):931-5. PubMed ID: 19281922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
